Phase I Study (First in Humans) of the Amblyomin-X in the Treatment of Patients With Advanced Solid Tumors Refractory or Without Indication / Access to Standard Treatment

Trial Profile

Phase I Study (First in Humans) of the Amblyomin-X in the Treatment of Patients With Advanced Solid Tumors Refractory or Without Indication / Access to Standard Treatment

Suspended
Phase of Trial: Phase I

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Amblyomin-X (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 19 Jun 2017 Status changed from not yet recruiting to suspended due to delay in the R & D stage.
    • 26 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top